Trial Profile
Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs TRC 102 (Primary) ; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma; Mesothelioma; Salivary gland cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 19 Oct 2023 Planned End Date changed from 31 Dec 2023 to 17 Oct 2024.
- 06 Oct 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 06 Oct 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.